Non-invasive bladder urothelial carcinoma
MONDO:0003930Stage 0 includes: 0a (Ta, N0, M0); 0is (Tis, N0, M0). Ta: Noninvasive papillary carcinoma. Tis: Carcinoma in situ: "flat tumor". N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)
Also known as: non-invasive bladder urothelial carcinoma, stage 0 bladder urothelial cancer, stage 0 bladder urothelial carcinoma, stage 0 bladder urothelial carcinoma aJCC v6, stage 0 bladder urothelial carcinoma aJCC v6 and v7, stage 0 bladder urothelial carcinoma aJCC v7, stage 0 transitional cell carcinoma of bladder, stage 0 transitional cell carcinoma of the bladder
2935 clinical trials for this condition and its sub-types, 167 tagged with Non-invasive bladder urothelial carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Non-invasive bladder urothelial carcinoma
-
Bladder carcinoma in situ 30 trials
-
New bladder cancer drug delivered directly into bladder shows early promise
Disease control Stopped earlyThis early-phase trial tested enfortumab vedotin, a drug placed directly into the bladder via a catheter, in 37 people with a type of bladder cancer that did not respond to standard BCG therapy. The main goals were to check safety and side effects, and to see if the drug could he…
Phase 1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy drug shows promise for tough bladder cancer cases
Disease control Stopped earlyThis phase II trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or with another agent in 296 people with high-risk non-muscle-invasive bladder cancer that did not respond to standard BCG therapy. Participants received the drug intravenously every three weeks. The…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Bladder cancer drug combo trial halted early – what does it mean?
Disease control Stopped earlyThis phase 3 trial tested whether adding nivolumab (an immunotherapy drug) to standard BCG treatment could help people with high-risk bladder cancer that came back after BCG alone. Only 13 people enrolled before the study was stopped early, so we don't have clear results on wheth…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC